Eravacycline

  • TRADE NAME: Xerava (Tetraphase Pharms Inc)
  • INDICATIONS: treatment of complicated intra-abdominal infections in patients 18 years of age and older.
  • CLASS: Antibacterial, tetracycline
  • HALF-LIFE: 20 hours

FDA APPROVAL DATE: 08/27/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
data insufficient to inform drug-associated risk of major birth defects and miscarriages.

Our database has 25 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
LOCAL


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric